Market Chatter: Novo Nordisk's Wegovy Delivers Increased Weight Loss in Triple-Dose Trials

Published 1 month ago • Sep 15, 2025 at 10:26 AM • Neutral

Auto

Related Stocks

LILY34.SA Eli Lilly and C... LLY.BE Eli Lilly and C... LLY.MU Eli Lilly and C... LLY.MX Eli Lilly and C... N1VO34.SA Novo Nordisk A/... NOVO-B.CO Novo Nordisk A/...

Novo Nordisk's (NVO) obesity treatment drug Wegovy led to increased weight loss in patients during t

PREMIUM

Upgrade to read this MT Newswires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? Sign in